Kenneth Alonzo Tucker

US Patent:

6514965, Feb 4, 2003

Filed:

Nov 7, 2000

Appl. No.:

09/706863

Inventors:

Alenka Tomazic - Gaithersburg MD
Liren Huang - Rockville MD
Kenneth D. Tucker - Frederick MD

Assignee:

Antex Pharma Inc. - Gaithersburg MD

International Classification:

C07D48700

US Classification:

51421207, 540523

Abstract:

This invention relates to substituted 1-benzazepines and derivatives thereof useful as antibacterial agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria or inhibiting bacterial growth.

US Patent:

6541616, Apr 1, 2003

Filed:

Oct 1, 1998

Appl. No.:

09/164714

Inventors:

Kenneth Tucker - Germantown MD
Ulrich F. Tillmann - Olney MD

Assignee:

Antex Biologics Inc. - Gaithersburg MD

International Classification:

C12N 1511

US Classification:

536 231, 536 2332, 4353201

Abstract:

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively âOMP21â), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.

US Patent:

7341727, Mar 11, 2008

Filed:

May 3, 1996

Appl. No.:

08/642712

Inventors:

Kenneth Tucker - Germantown MD, US
Laura Plosila - Cary NC, US

Assignee:

Emergent Product Development Gaithersburg Inc. - Gaithersburg MD

International Classification:

A61K 39/00

US Classification:

4241901, 530324, 530328

Abstract:

The invention discloses the outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to and OMP106 polypeptides and OMP106-derived polypeptides in animals.

US Patent:

20080145916, Jun 19, 2008

Filed:

Oct 26, 2007

Appl. No.:

11/925586

Inventors:

Kenneth Tucker - Germantown MD, US
Laura Plosila - Cary NC, US

International Classification:

C12N 1/20
C07K 16/12

US Classification:

4352521, 5303879

Abstract:

The invention discloses the outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to and OMP106 polypeptides and OMP106-derived polypeptides in animals.

US Patent:

20030235592, Dec 25, 2003

Filed:

Feb 19, 2003

Appl. No.:

10/369299

Inventors:

Kenneth Tucker - Germantown MD, US
Ulrich Tillmann - Olney MD, US

Assignee:

Antex Biologics, Inc.

International Classification:

A61K039/02
C07H021/04
C12P021/02
C12N001/21
C07K014/195

US Classification:

424/190100, 536/023700, 435/069300, 435/320100, 435/252300, 530/350000

Abstract:

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.